Skip to main content

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Completed · Phase 3 · NCT05172726

Conditions: Plaque Psoriasis

At a glance

Research payments reported, 2025
$112,606
U.S. investigators named
10
Sites paid
9
Planned or actual enrollment
58

About the trial

Sponsor
Organon and Co
Tested
tapinarof cream, 1% (drug)
Dates
Started 2021-12-02; completion 2026-10-14
Results posted
Not yet

This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.

From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Organon Llc reported $112,606 in research payments for this study in 2025 (43 payments).

Products named: Vtama

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Northwestern University-M.s.s $29,317
  • Wright State Physicians $22,951
  • Rm Medical Research, Inc. $17,483
  • Northwest Arkansas Clinical Trials Center. PLLC $16,575
  • Shireen V. Guide, MD, Inc. $13,009
  • Dermatology Specialists of Spk-Svip $4,732
  • San Marcus Research Clinic Inc. $3,406
  • Options Research Group, LLC $2,666
  • First Oc Dermatology-Vip $2,467

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.